Replies to post #354020 on Innovation Pharmaceuticals Inc (IPIX)

[TheDane]

Those are big ifs. Ipix would be working on other diseases and c-19 wouldn’t even be in the mix if there was no coronavirus pandemic. Neither would the RBLs have studied Brilacidn and recommended it for human trials.

[Lemoncat]

It wasn't even on the radar prior to the Pandemic. But that doesn't mean we need a pandemic to make it work from here on out:

Influenza doesn't shut everything down but it has 500,000 hospitalizations each year in the United States. COVID will be remaining with us permanently. A disease this infectious that can mutate and reinfect as COVID appears to do will last a long time.

Assuming COVID can be brought down to that level:

500,000 hospitalizations x $200/treatment = $100,000,000/year in revenue in the United States alone.

What does that do to a company with a $120M market cap? Aside from fully funding the company and the pipeline it likely shoots the stock up to $3-5B+.

That ignores all the potential use in Influenza, Pneumonia, and other viral infections.

Go IPIX!